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Abstract
Objective
Immune myopathies with perimysial pathology (IMPP) have a combination of damage to
perimysial connective tissue and muscle ﬁber necrosis, more prominent near the perimysium. We studied the clinical and laboratory correlates of patients with pathologically
deﬁned IMPP.
Methods
This is a retrospective chart and pathology review of 57 consecutive patients with IMPP
myopathology and, for comparison, 20 patients with dermatomyositis with vascular pathology
(DM-VP).
Results
Compared with DM-VP, IMPP patients more commonly had interstitial lung disease (ILD) (p
< 0.01), Raynaud phenomenon (p < 0.05), mechanic’s hands (p < 0.05), arthralgias (p < 0.001),
and a sustained response to immunomodulatory therapy (p < 0.05), and less frequently had
a concurrent malignancy (p < 0.01). IMPP patients had higher serum creatine kinase values (p <
0.05), more frequent serum Jo-1 (p < 0.03) or SSA/SSA52 autoantibodies (p < 0.05), and less
frequent antinuclear antibodies (p < 0.01). IMPP patients with serum Jo-1/antisynthetase
antibodies were more likely to have ILD (p < 0.05) and inﬂammatory arthritis (p < 0.05) than
IMPP patients without these antibodies.
Conclusions
IMPP myopathology is associated with an increased risk of ILD, Raynaud phenomenon,
mechanic’s hands, and inﬂammatory arthritis when compared with another immune myopathy
(DM-VP). IMPP patients require regular screening for ILD, particularly those with antisynthetase antibodies. The absence of myositis-speciﬁc autoantibodies in a large percentage of
IMPP patients emphasizes the important role for myopathology in identifying patients at higher
risk of severe comorbid conditions such as ILD.

From the Department of Neurology, Washington University School of Medicine, St. Louis, MO.
Funding information and disclosures are provided at the end of the article. Go to Neurology.org/nn for full disclosure forms.
The Article Processing Charge was funded by the authors.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading
and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

1

Glossary
DM-VP = dermatomyositis with vascular pathology; HMGCR = hydroxy-methyl-glutaryl-coenzyme A reductase; IIM =
immune and inﬂammatory myopathy; ILD = interstitial lung disease; IMPP = immune myopathies with perimysial pathology;
MHC = major histocompatibility complex; MSA = myositis-speciﬁc antibody; RIIM = regional ischemic immune myopathy;
UEA = Ulex europaeus agglutinin.

Acquired immune and inﬂammatory myopathies (IIMs) are
a heterogeneous group of disorders. Classiﬁcation schemes
have been based on clinical, autoantibody, or myopathologic
features.1–5 Serum antibodies to aminoacyl-tRNA synthetases
are associated with a multisystem syndrome that includes IIM.
Clinical manifestations include myopathy, interstitial lung
disease (ILD), arthritis, Raynaud phenomenon, and skin rash.
The commonest antisynthetase antibody, anti-Jo-1, is directed against histidyl tRNA synthetase. Myopathology in
patients with anti-Jo-1 antibodies includes damage to perimysial connective tissue and muscle ﬁbers.4,6,7 Perimysial
connective tissue pathology includes damaged structures with
fragmentation and scattered histiocytic cells. Muscle ﬁber
pathology includes necrosis and regeneration, more prominent in regions neighboring the perimysium. We have termed
myopathies with this combined pattern of damage, immune
myopathies with perimysial pathology (IMPP).4 IMPP also
occurs with serum antibodies to hydroxy-methyl-glutarylcoenzyme A reductase (HMGCR),8 a nonaminoacyl-tRNA
synthetase antigen. Other patients with IMPP have no associated myositis-speciﬁc antibodies (MSA).
This study examined clinical and laboratory features of a cohort of consecutive patients with IMPP evaluated at our institution. We compared IMPP patients with a cohort of
patients with a diﬀerent immune myopathy syndrome, dermatomyositis with vascular pathology (DM-VP). DM-VP
diﬀers pathologically from IMPP, as it is a myovascular disorder. Muscle ﬁber changes are generally atrophy, rather than
the necrosis seen in IMPP.4,9 Our results show that IMPP is
associated with myopathy syndromes having multisystem
features involving muscle, lungs, skin, and joints.

Methods
Patients
We retrospectively reviewed charts, laboratory data, and
muscle biopsies from 57 consecutive patients with muscle
biopsies interpreted as having an IMPP (table 1 and ﬁgure)
who had been clinically evaluated at Washington University
School of Medicine in Saint Louis between 1990 and 2013.
IMPP biopsies had acid phosphatase positive cells in perimysial connective tissue and evidence of myopathy deﬁned as
one of the following: abnormal variation in the muscle ﬁber
size, necrosis or regeneration, or major histocompatibility
complex (MHC) Class I upregulation by muscle ﬁbers. Some
patients in this group were previously reported.6,10 For comparison, we reviewed a consecutive series of 20 patients with
2

biopsies interpreted as DM-VP (Table 1 and ﬁgure). DM-VP
biopsies had vascular pathology, with abnormal endomysial
capillaries or perivascular lymphocytic foci and perifascicular
myopathy with muscle ﬁber atrophy, reduced cytochrome
oxidase staining, or increased MHC Class I expression.
Definition of clinical features
ILD was deﬁned by imaging features, pulmonary function
tests, biopsy data, and/or expert opinion of a pulmonologist.
Inﬂammatory arthritis was deﬁned by imaging features and/or
expert opinion of a rheumatologist. Dermatologic features
were deﬁned by clinical description (i.e., mechanic’s hands,
Gottron sign), biopsy data, and/or expert opinion of a dermatologist. Myalgias and Raynaud phenomenon were deﬁned
by the clinicians’ documentation as present or absent. Dysphagia was deﬁned by objective testing (modiﬁed barium
swallow or endoscopic evaluation of swallowing) and/or expert opinion of a speech therapist. Paraneoplastic syndromes
were deﬁned as a concurrent cancer diagnosis within a 5-year
period preceding or subsequent to the myopathy diagnosis.
Laboratory data
The initial serum creatine kinase and aldolase values (IU/L)
are reported. Panels of serum MSA were evaluated by clinical
laboratories in Oklahoma or California. HMGCR antibodies
were tested at Washington University in St. Louis.8 Electromyographic evidence of an “irritable” myopathy was deﬁned
as the presence of increased insertional or spontaneous activity (in the form of ﬁbrillations, positive sharp waves, or
myotonic/repetitive discharges), motor unit potentials of
reduced amplitude and duration, and early recruitment.
Histochemical and
immunohistochemical evaluation
Cryostat sections of rapidly frozen muscle were processed as
previously described.6,11 Immunohistochemical stains were
performed on muscle cryosections with paired controls on the
same glass slide. Primary antibodies used in this study were
CD4, CD20, C5b-9 complement (membrane attack complex)
(Sigma-Aldrich, St. Louis, MO), and class I human MHC (US
Biological, Swampscott, MA). Ulex europaeus agglutinin I
lectin (UEA, Sigma-Aldrich) was used to visualize the vascular
endothelium. In most cases, the pathologists interpreting biopsies (A.P. and R.C.B.) were blinded to results of MSA
testing.
Statistical analysis
The Fisher exact test was used to compare categorical variables. Independent 2-tailed t-tests were used to compare and
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Table 1 Myopathology: IMPP and DM-VP groups
IMPP
Histochemistry

DM-VP

p-Value

Odds ratio

%

n/57

%

n/20

Acid phosphatase+ cells

100

57

20

4

4 × 10213

—

Alkaline phosphatase+

65

37

20

4

0.0007

7.4

Fragmentation

58

33

20

4

0.004

5.5

18

10

95

19

7 × 10210

0.011

Necrosis/regeneration

88

50

20

4

5 × 1028

28.6

Atrophy, perifascicular

21

12

95

19

0.000004

0.014

212

0.006

Perimysium

Capillaries
Alkaline phosphatase+
Muscle fibers

COX-fibers, perifascicular

11

6

95

19

%

n/41

%

n/15

Reduced (UEA stain)

20

8

80

12

0.00006

0.061

C5b-9 deposition

29

12

67

10

0.015

0.41

MHC-1 expression

85

35

100

15

0.18

0

MHC-1+: perifascicular > other

24

10

60

9

0.024

0.22

85

35

100

15

0.18

0

20

8

80

12

0.00006

0.061

Immunohistochemistry

6 × 10

Capillaries

Muscle fibers

Immune cells
CD4+
CD20

+

Abbreviations: COX = cytochrome oxidase; DM-VP = dermatomyositis with vascular pathology; IMPP = immune myopathies with perimysial pathology; MHC =
major histocompatibility complex; UEA = Ulex europaeus agglutinin. Bold values are statistically significant.

report quantitative variables. A p value <0.05 was considered
statistically signiﬁcant between groups. Because this was
a retrospective exploratory study, we did not correct for
multiple comparisons. When clinical or laboratory data were
unavailable, the subject was not included in the analysis for
that feature.
Standard protocol approvals, registrations,
and patient consents
The Human Studies Committee of Washington University in
Saint Louis approved all procedures.

Results
Pathology of IMPP and DM-VP
IMPP patients were chosen based on the presence of perimysial pathology, highlighted by acid phosphatase positive
perimysial cells and alkaline phosphatase staining of the
perimysium, and these features were less common in the
Neurology.org/NN

DM-VP group (table 1; ﬁgure). DM-VP patients were chosen
based on the presence of vascular pathology, as deﬁned by any
of the following features, lymphocytic foci surrounding larger
vessels in vascular perimysium, alkaline phosphatase staining
or C5b-9 deposition on endomysial capillaries, or loss of
endomysial capillaries on UEA, and these features were less
common in the IMPP group. Muscle ﬁber necrosis and regeneration, features not part of the selection process, were
more common in the IMPP group. The most common
pathologic change in muscle ﬁbers in the DM-VP group was
atrophy. Lymphocyte foci containing CD20 B-cells were
more common in DM-VP. CD8 positive T-lymphocytes were
uncommon in both DM-VP and IMPP.
Clinical features of IMPP and DM-VP
Both IMPP (70%) and DM-VP (80%) groups were predominantly female. Onset ages varied widely in both IMPP
(16–83 years) and DM-VP (7–78 years) groups (table 2).
There were no diﬀerences in age, sex, race, or frequencies of
weakness, dysphagia, and skin rash comparing the IMPP and
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Figure Comparative myopathology of immune myopathies with perimysial pathology (IMPP) and dermatomyositis with
vascular pathology (DM-VP)

IMPP myopathology includes perimysium that is
widened and damaged (A; H&E stain), occupied by
histiocytic cells (C; acid phosphatase stain), and
stained by alkaline phosphatase (E). Muscle fiber
damage includes necrosis, (membrane attack
complex [C5b-9] deposited in fiber cytoplasm [G]),
more prominent near the perimysium. DM-VP
myopathology includes muscle fiber pathology
with perifascicular atrophy without necrosis (B;
H&E stain) and metabolic changes, including reduced staining on cytochrome oxidase (H). DM-VP
vascular pathology includes perivascular (perimysial) lymphocytic inflammation (D; Congo red
stain) and endomysial capillary changes with increased alkaline phosphatase staining (F). Scale
bar = 100 μM (Panels A–H).

DM-VP groups. Systemic features common in anti-Jo-1 antibody syndromes were all more common in IMPP patients
than DM-VP patients. Features more common in IMPP included mechanic’s hands, Raynaud phenomenon, ILD, joint
disorders, and serum antisynthetase antibodies. IMPP
patients were less likely to have an associated malignancy or to
die of a malignancy, compared with DM-VP. Causes of death
in the IMPP group were ILD (2), neoplasm (2), and congestive heart failure (1). All deaths (5) in the DM-VP group
were associated with neoplasm. ILD and arthritis were more
4

common in IMPP patients with antisynthetase antibodies
compared to those without antisynthetase antibodies (ILD =
63% vs 26%, respectively, p = 0.03; arthritis = 94% and 61%,
respectively, p = 0.03). Arthritis was also more common in
antisynthetase antibody-negative IMPP compared with DMVP (61% vs 25%, p = 0.03). ILD showed a trend toward
greater frequency in antisynthetase antibody-negative IMPP
compared with DM-VP (26% and 10%, respectively), but the
diﬀerence was not statistically signiﬁcant. Other clinical, laboratory, electrodiagnostic, and myopathologic features were
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Table 2 Clinical features of IMPP and DM-VP
IMPP

DM-VP

%

n

%

n

p-Value

Sex: female

70

40/57

80

16/20

0.56

Race: white

75

43/57

65

13/20

0.39

Odds ratio

Epidemiology

Onset age (y)

47 ± 2

45 ± 5

0.84

Clinical features
Muscle
Weakness

83

45/54

95

19/20

0.27

0.26

Dysphagia

57

29/51

60

12/20

1

0.88

Myalgias

71

37/52

70

14/20

1

1.1

Rash

76

39/51

75

15/20

1

Mechanic’s hands

33

16/49

5

1/20

0.028

9.2

Raynaud phenomenon

22

11/50

0

0/20

0.027

-

Lung (ILD)

43

23/54

10

2/20

0.011

6.7

Joints (arthritis)

73

38/52

25

5/20

0.0003

8.1

Frequency

5

3/55

35

7/20

0.003

0.11

Cause of death

4

2/55

25

5/20

0.013

0.11

Skin

Neoplasm

Abbreviations: DM-VP = dermatomyositis with vascular pathology; ILD = interstitial lung disease; IMPP = immune myopathies with perimysial pathology. Bold
values are statistically significant.

similar in antisynthetase antibody-negative and antibodypositive IMPP subgroups (data not shown).
Laboratory features of IMPP and DM-VP
Serum creatine kinase and aldolase were 8-fold and 4-fold
higher (p = 0.04) in the IMPP group (table 3), consistent with
the muscle ﬁber necrosis and regeneration that is common in
IMPP but rare in DM-VP (Table 1 and Figure A-H). Jo-1 (p <
0.03) and SSA (p < 0.05) antibodies were more common in
IMPP patients. Forty-six patients in the IMPP cohort and 17
patients in the DM-VP underwent MSA testing. In addition to
Jo-1 and HMGCR, the only other MSA present in the IMPP
cohort were EJ (2) and PL-12 (1), whereas Mi-2 (1) was the
only additional MSA identiﬁed in the DM-VP cohort. ANA was
more commonly positive in DM-VP than IMPP patients. Creactive protein and erythrocyte sedimentation rate values did
not diﬀer between the 2 groups. Electromyograms showing
“irritable” myopathy were similarly frequent in the 2 groups.
Response to treatment.
The myopathy in all but 1 IMPP patient (98%) had a sustained beneﬁcial response to immunomodulatory therapies,
as measured by strength testing, improvement/resolution of
Neurology.org/NN

myalgias, and/or reduction in muscle enzymes. Immunomodulatory therapies used in the IMPP group included oral
corticosteroids (n = 47); oral methotrexate (n = 25); pulse
intravenous methylprednisolone (n = 13); azathioprine (n =
12); mycophenolate mofetil (n = 7); rituximab (n = 7); and
intravenous immunoglobulin (n = 4). The myopathy in DMVP patients was less responsive to immunomodulatory therapy with only 14 (70%) subjects demonstrating a sustained
beneﬁcial response (p = 0.002). The immunomodulatory
therapies used in the DM-VP cohort were comparable to
those used in the IMPP cohort. Five of the 6 nonresponders in
the DM-VP cohort had paraneoplastic myopathies, suggesting that this factor likely accounted for the diﬀerence in
treatment responsiveness between groups.

Discussion
We have proposed that IIMs are usefully classiﬁed according
to patterns of involvement of diﬀerent tissues in muscle and
types of cellular and humoral immune features.4 In this study,
we compared patients with IMPP, whose distinctive myopathologic features include damage to perimysial connective
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Table 3 Laboratory and electrodiagnostic features: IMPP vs DM-VP
IMPP

DM-VP

p-Value

Creatine kinase (U/L)

3,543 ± 760

457 ± 670

0.04

Aldolase (U/L)

45 ± 18

10 ± 4

0.04

Sedimentation rate (mm/h)

33 ± 5

26 ± 8

0.47

C-reactive protein (mg/L)

14 ± 7

5±2

0.07

Disease activity marker

%

n

%

n

p-Value

Odds ratio

ANA ≥1:160

51

23/45

89

16/18

0.009

0.13

Jo-1*

37

17/46

6

1/17

0.025

9.4

SSA/SSA52

23

9/40

0

0/18

0.045

—

HMGCR

40

8/20

14

1/7

0.4

4.0

77

30/39

82

14/17

0.74

0.71

Antibody marker

Electromyography: irritable myopathy

Abbreviations: ANA = antinuclear antibody; DM-VP = dermatomyositis with vascular pathology; HMGCR-3 = hydroxy-3-methyl-glutaryl-coenzyme A reductase;
IMPP = immune myopathies with perimysial pathology. Bold values are statistically significant.
* Additional myositis-specific antibody (MSA) identified in the IMPP group included EJ (2) and PL-12 (1), while Mi-2 (1) was the only other MSA identified in the
DM-VP group.

tissue, muscle ﬁber necrosis, and histiocytic inﬂammatory
cellularity, to DM-VP, a disorder with large and small vessel
damage, muscle ﬁber atrophy, but not necrosis, and lymphocytic perivascular inﬂammation (Table 1; ﬁgure). The
distinctive pathologic features of IMPP and DM-VP in this
study are consistent with previously reported patterns.4,6,7,9,12
Several systemic and laboratory features of patients with
IMPP diﬀered from DM-VP. IMPP patients more often had
joint disorders and ILD. Neoplasm occurrence and cancerrelated deaths were less frequent in IMPP. The type of skin
pathology diﬀered between the groups. Mechanic’s hands and
Raynaud phenomenon were nearly exclusive to IMPP. Serum
Jo-1 antibodies were also more frequent in IMPP (37% vs 6%
in DM-VP).
Clinical syndromes in patients with IMPP myopathology
showed some features that were also common in DM-VP and
immune myopathies in general. These features included female predominance, wide variability in age at onset, weakness
that is proximal greater than distal and symmetric, dysphagia,
and myalgias. The disease course was subacute or chronic,
with durations over months to years.
The frequency of skin disorders was similar in IMPP and DMVP groups. Clinically, approximately 75% of both groups
would have been characterized as dermatomyositis by commonly used criteria. Diﬀerences in muscle pathology suggest
that immune dermatomyopathies may actually comprise
several distinct clinical and pathologic syndromes. IMPP
dermatomyopathy syndromes seem likely to be due to connective tissue damage, while DM-VP is probably a vascular
6

disorder. Another dermatomyopathy syndrome, regional ischemic immune myopathy (RIIM), has prominent vascular
pathology with muscle ﬁber necrosis occurring in border-zone
regions of muscle, a diﬀerent pattern from IMPP and DMVP.13 Both of these vascular dermatomyopathies (RIIM and
DM-VP) are associated with an increased frequency of neoplasms and likely account for a substantial proportion of the
established association between dermatomyositis (as deﬁned
by other criteria) and malignancy.14,15 Overall, it is likely that
the dermatomyopathies, or “dermatomyositis,” should be
considered a group of disorders with varying comorbid conditions beyond skin and muscle, rather than a single
homogeneous disease.
IMPP muscle pathology is associated with a consistent multisystem disorder, involving muscle, skin, lungs and joints,
which is similar to that associated with serum anti-Jo-1, and,
more generally, antisynthetase, antibodies. However, most of
our patients did not have antisynthetase antibodies, rendering
muscle biopsy considerably more sensitive for deﬁning these
syndromes than serum antibody testing.
Although antisynthetase antibodies commonly occur in
a subset of IMPP, the relationship of these antibodies directed
against intracellular antigens to disease pathogenesis remains
unclear. The pattern of muscle pathology suggests that the
antigenic targets in IMPP are likely related to connective
tissue, which could explain the pattern of multisystem involvement. Acid phosphatase–positive perimysial histiocytes
in IMPP are a notable myopathologic diﬀerence from the
perivascular lymphocytes present in DM-VP. It is possible
that these acid phosphatase positive histiocytes, a signature
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feature of IMPP, are ultimately responsible for the muscle
ﬁber necrosis typical of this condition, perhaps via cytokinemediated pathways diﬀerent from those associated with
muscle ﬁber atrophy and regeneration in other forms of immune myopathy.16 It is well established in hereditary disorders that abnormalities in connective tissue proteins can
produce severe myopathies.17–20 Further search for the speciﬁc tissue autoantigens (possibly in connective tissue), and
how perimysial pathology leads to muscle ﬁber necrosis, in
IMPP will be important.
Our results are the outcome of a retrospective study of muscles
from patients, most of whom presented to neurologists with
primary complaints of weakness. Prospective studies would be
useful to test our ﬁndings that IMPP is associated with distinctive multisystem disorders in adults and children. Studies of
the frequency and types of IMPP myopathy and lung and skin
pathology in patients presenting with ILD or skin disorders
could provide further information about systemic immune
disorders aﬀecting connective tissue. Larger series could also
evaluate whether antisynthetase and other serum autoantibodies in IMPP patients such as anti-HMGCR are associated
with speciﬁc subgroups of pathologic changes and clinical
system involvement. A limitation of our study, given its retrospective nature, is that we could not guarantee that diagnostic
testing, including MSA testing, was uniform across all subjects.
While over 80% of the subjects in both cohorts did undergo
some form of MSA testing, this study includes subjects evaluated over a 24-year period that coincided with a substantial
increase in the number of myositis-speciﬁc autoantibodies
available for clinical testing. Future prospective studies, ideally
with serum banking to allow for retrospective testing of newly
identiﬁed autoantibodies, are ultimately necessary to determine
the actual prevalence of MSA in these disorders.
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